Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature

Anat Gafter-Gvili; Ron Ram; Uzi Gafter; Ofer Shpilberg; Pia Raanani

doi:10.1016/j.leukres.2009.07.009

Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature

Leuk Res. 2010 Jan;34(1):123-7. doi: 10.1016/j.leukres.2009.07.009. Epub 2009 Jul 28.

Authors

Anat Gafter-Gvili¹, Ron Ram, Uzi Gafter, Ofer Shpilberg, Pia Raanani

Affiliation

¹ Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

PMID: 19640584
DOI: 10.1016/j.leukres.2009.07.009

Abstract

Imatinib mesylate (IM), nilotinib and dasatinib are tyrosine kinase inhibitors (TKIs) that have revolutionized the treatment of chronic myeloid leukemia (CML). Data regarding the effect of TKIs on the kidney or their safety in patients with renal failure is lacking. We describe a patient with CML who developed renal failure during IM treatment which resolved upon discontinuation of the drug and was not exacerbated by the administration of nilotinib. The literature reporting on the association between TKIs and renal failure is reviewed and the postulated mechanisms including tubular dysfunction caused by the drug or tumor lysis syndrome are discussed.

Publication types

Case Reports
Review

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Middle Aged
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors*
Renal Insufficiency / chemically induced*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Protein-Tyrosine Kinases